SCHEMBL21887955

SCHEMBL21887955

NC(=O)c1ncn([C@@H]2O[C@H](COP(=O)(O)c3ccccc3)[C@@H](O)[C@H]2O)n1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
ALDH1A1 P00352 1/20 0.61
GLA P06280 1/20 0.61
EIF4E P06730 1/20 0.61
CYP3A4 P08684 1/20 0.61
TOP1 P11387 1/20 0.61
TSHR P16473 1/20 0.61
ADORA1 P30542 1/20 0.61
THPO P40225 1/20 0.61
PMP22 Q01453 1/20 0.61
ATIC P31939 2/20 0.48
FBP1 P09467 1/20 0.48
PNP P00491 2/20 0.47
DNPH1 O43598 4/20 0.44
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
P2RY12 Q9H244 1/20 0.42
LDHA P00338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribavirin Monophosphate SCHEMBL10882076 0.87 LMNA (0.69) LMNASMN1; SMN2ALDH1A1GLAEIF4E
Ribavirin Monophosphate SCHEMBL12727825 0.87 LMNA (0.69) LMNASMN1; SMN2ALDH1A1GLAEIF4E
Ribavirin Monophosphate SCHEMBL11202379 0.87 LMNA (0.69) LMNASMN1; SMN2ALDH1A1GLAEIF4E
Ribavirin Monophosphate SCHEMBL1508870 0.87 LMNA (0.69) LMNASMN1; SMN2ALDH1A1GLAEIF4E
Ribavirin Monophosphate SCHEMBL11654617 0.86 LMNA (0.67) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL24024421 0.85 LMNA (0.66) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL20277543 0.85 LMNA (0.66) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL20277606 0.85 LMNA (0.66) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL24024420 0.85 LMNA (0.66) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL6917127 0.84 LMNA (0.67) LMNASMN1; SMN2ALDH1A1GLAEIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353660-A1 Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs OCTAGON THERAPEUTICS INC. (US) 2021-11-18 US disclosed
WO-2020072931-A2 PRE-ACTIVATED NUCLEOSIDE IMPDH INHIBITORS AS ANTI-INFECTIVE DRUGS OCTAGON THERAPEUTICS INC. (US) 2020-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353660-A1 Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs IMPDH1, IMPDH2, PNP LMNA 1199/4885SMN1; SMN2 4411/4885ALDH1A1 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.